We have updated our privacy policy. If you have any question, contact us at privacy@scicrunch.org. Dismiss and don't show again

Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia.

Cancer cell | Nov 13, 2012

We report that t(1;19) ALL cells universally exhibit expression of and dependence on the cell surface receptor ROR1. We further identify t(1;19) ALL cell sensitivity to the kinase inhibitor dasatinib due to its inhibition of the pre-B cell receptor (pre-BCR) signaling complex. These phenotypes are a consequence of developmental arrest at an intermediate/late stage of B-lineage maturation. Additionally, inhibition of pre-BCR signaling induces further ROR1 upregulation, and we identify distinct ROR1 and pre-BCR downstream signaling pathways that are modulated in a counterbalancing manner-both leading to AKT phosphorylation. Consistent with this, AKT phosphorylation is transiently eliminated after dasatinib treatment, but is partially restored following dasatinib potentiation of ROR1 expression. Consequently, ROR1 silencing accentuates dasatinib killing of t(1;19) ALL cells.

Pubmed ID: 23153538 RIS Download

Mesh terms: Chromosomes, Human, Pair 1 | Chromosomes, Human, Pair 19 | Dasatinib | Gene Expression Regulation, Neoplastic | Gene Silencing | Humans | Phosphorylation | Pre-B Cell Receptors | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Protein Kinase Inhibitors | Proto-Oncogene Proteins c-akt | Pyrimidines | Receptor Tyrosine Kinase-like Orphan Receptors | Signal Transduction | Thiazoles | Translocation, Genetic

Research resources used in this publication

None found

Research tools detected in this publication

None found

Data used in this publication

None found

Associated grants

  • Agency: NCI NIH HHS, Id: K99 CA151457
  • Agency: NCI NIH HHS, Id: R01 CA157644
  • Agency: NCI NIH HHS, Id: R00 CA151457
  • Agency: Howard Hughes Medical Institute, Id: 4R00CA151457-03
  • Agency: NCI NIH HHS, Id: UL1 RR024140
  • Agency: NCRR NIH HHS, Id: P30 CA069533
  • Agency: NCI NIH HHS, Id: R01 CA137060
  • Agency: NCI NIH HHS, Id:

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

We have not found any resources mentioned in this publication.